Compare Cassava Sciences Inc (FLNA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Msci Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Msci Inc trades at $632.67 (market cap $45.26B). The key difference: Msci Inc is far larger — about 851.7× Cassava Sciences Inc's market cap, and Msci Inc pays a 1.32% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MSCI | |
|---|---|---|
Market Cap | $53.14M | $45.26B |
Sector | Health | Financials |
52-Week High | $4.64 | $643.83 |
52-Week Low | $1.09 | $511.84 |
Enterprise Value | -$33.43M | $51.43B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
MSCI trades at $626.59, up 2.48% today, with strong technical momentum as the stock approaches resistance at $628. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.55 versus $4.44, maintaining a three-quarter earnings beat streak. Recent strategic partnerships with UBS and the acquisition of First Street highlight growth initiatives in private markets and climate risk analytics. Valuation metrics show a P/E of 35.51 and P/S of 14.5, reflecting premium pricing for consistent performance.
The outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and a price target of $718.14 offering 15% upside potential. Key risks include high debt levels at $4.51 billion and sensitivity to financial market conditions. The upcoming Q2 2026 earnings report on July 21, 2026, will be critical for validating growth trajectory amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
